Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says the first patient in its multicentre Modi-1 clinical trial has been dosed at Imperial College London, Hammersmith Hospital. The study, it explains, is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. Modi-1 will be administered alone or in combination with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours.
Modi-1 is the first candidate in Scancell's Moditope platform and the study will recruit up to 108 patients in up to 20 UK clinical trial sites, it says. Company expects early safety and immunogenicity data to be available in the second half of 2022 and efficacy data in 2023.
Chief Executive Officer Lindy Durrant says: "This is the first time we have taken a product from our Moditope platform into cancer patients and it is a highly significant milestone for the company. We are optimistic about the broad clinical utility of Modi-1 and, following safety assessments in the first few cohorts of patients, we intend to rapidly recruit patients across all four cancers."
Current stock price: 13.00 pence
12-month change: down 40%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)